PlaqueTec raised $5M in an oversubscribed round to expand its work on intracoronary blood-protein biomarkers for coronary artery disease. The company’s BIOPATTERN clinical trial uses a device that samples proteins at the site of plaque formation to build a differentiated proteomic dataset. PlaqueTec said it is using proteomic and clinical data to construct BioCarta, a database intended for drug target selection and patient stratification. The company also said it is in discussions with potential pharma and biotech partners. Chairman Martin Stapleton linked the financing to runway for building the “high-resolution, intracoronary data asset” ahead of broader partnering efforts.